



**SDI Review Form 1.6**

Journal Name:	<a href="#">Journal of Pharmaceutical Research International</a>
Manuscript Number:	<b>Ms_JPRI_56916</b>
Title of the Manuscript:	<b>Optimizing the use of hydroxychloroquine in management of COVID-19 given its pharmacological profile</b>
Type of the Article	<b>Review Article</b>

**General guideline for Peer Review process:**

This journal's peer review policy states that **NO** manuscript should be rejected only on the basis of '**lack of Novelty**', provided the manuscript is scientifically robust and technically sound. To know the complete guideline for Peer Review process, reviewers are requested to visit this link:

(<http://www.sciencedomain.org/page.php?id=sdi-general-editorial-policy#Peer-Review-Guideline>)

**PART 1: Review Comments**

	<b>Reviewer's comment</b>	<b>Author's comment</b> (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)
<b>Compulsory</b> REVISION comments	<p><b>Introduction</b>                      "approximately 80 [...] : give reference and precise statistics.                      References are needed in the first paragraph of the part : SARS-CoV-2 characteristics.                      Beware of too much enthusiasm, HCQ is no "one of the most promising repurposed drug" anymore.                      The article of Gautret et al 2020a is highly debated and could not be considered by health authorities, as the (minor) results could be due to azithromycin and not HCQ. please modify.                      Reference have to be standardized.                      When using acronyms, please introduce them (example : T2DM)                      The last paragraph before reference is very very surprising and give impression that the writing work has not be completely finished...</p>	
<b>Minor</b> REVISION comments	<p>Reference published before 2019 could definitively not focus on COVID19 (end of the fourth page)                      Figure 2 is missing.                      Wang et al reported high selectivity of CQ for SARS-CoV&amp; rather than host cells, but what about HCQ?                      In vivo has to be written in italic.</p>	
<b>Optional/General</b> comments		



[SDI Review Form 1.6](#)

**PART 2:**

	<b>Reviewer's comment</b>	<b>Author's comment</b> <i>(if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)</i>
<b>Are there ethical issues in this manuscript?</b>	<i>(If yes, Kindly please write down the ethical issues here in details)</i>	

**Reviewer Details:**

Name:	<b>Pichon Maxime</b>
Department, University & Country	<b>University Hospital of Poitiers, France</b>